Demonstrability of the glycoprotein A-80 in postradiation prostatic carcinoma

Cristina Magi-Galluzzi, Szabo Nagy, David G. Bostwick, Liang Cheng, Victor E. Gould

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Radiation therapy results in significant morphological changes in prostatic carcinoma, including decreased cancer size, acinar shrinkage and distortion, cytoplasmic vacuolization, and nuclear pyknosis. Benign acini usually display enlarged, atypical cells with hyperchromatic nuclei. These changes confound the evaluation of limited postradiation samples. The glycoprotein A-80 is known to be upregulated in prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma. In this study, we assessed the expression of A-80 in radiation-treated prostatic carcinoma. Paraffin sections from 64 postradiation prostatic carcinomas obtained at salvage prostatectomy were immunostained with a monoclonal antibody to A-80; selected sections were doubly immunostained with antibodies to A-80 and various cytokeratin polypeptides. All cases showed readily detectable and often intense staining in the cytoplasm of cancer cells and in intraluminal material of malignant acini. The extent and intensity of the reactions were independent of cancer size and grade. Strong reactions were seen in preserved and distorted acini, clear cell areas, single cancer cells, and in colloid pools with few or no recognizable cancer cells. PIN was present in 34 cases (53%), of which 27 (79%) stained strongly for A-80; atrophic and hyperplastic acini generally did not stain, irrespective of the degree of cellular atypia. The A-80 glycoprotein appears remarkably durable and is readily demonstrable in postradiation prostatic carcinoma despite profound architectural and cytologic changes. This characteristic may prove useful in evaluating small samples for confirmation of diagnosis and determination of extent of residual or recurrent prostatic carcinoma after radiation therapy.

Original languageEnglish (US)
Pages (from-to)1474-1478
Number of pages5
JournalHuman pathology
Volume30
Issue number12
DOIs
StatePublished - Jan 1 1999

Fingerprint

Glycoproteins
Carcinoma
Prostatic Intraepithelial Neoplasia
Neoplasms
Radiotherapy
Acinar Cells
Colloids
Prostatectomy
Keratins
Paraffin
Cytoplasm
Coloring Agents
Monoclonal Antibodies
Radiation
Staining and Labeling
Peptides
Antibodies

Keywords

  • A-80 glycoprotein
  • Immunohistochemistry
  • Postradiation
  • Prostatic carcinoma
  • Radiation therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Demonstrability of the glycoprotein A-80 in postradiation prostatic carcinoma. / Magi-Galluzzi, Cristina; Nagy, Szabo; Bostwick, David G.; Cheng, Liang; Gould, Victor E.

In: Human pathology, Vol. 30, No. 12, 01.01.1999, p. 1474-1478.

Research output: Contribution to journalArticle

Magi-Galluzzi, Cristina ; Nagy, Szabo ; Bostwick, David G. ; Cheng, Liang ; Gould, Victor E. / Demonstrability of the glycoprotein A-80 in postradiation prostatic carcinoma. In: Human pathology. 1999 ; Vol. 30, No. 12. pp. 1474-1478.
@article{db8fa22b56de44ff9a7946fc7e2f4c70,
title = "Demonstrability of the glycoprotein A-80 in postradiation prostatic carcinoma",
abstract = "Radiation therapy results in significant morphological changes in prostatic carcinoma, including decreased cancer size, acinar shrinkage and distortion, cytoplasmic vacuolization, and nuclear pyknosis. Benign acini usually display enlarged, atypical cells with hyperchromatic nuclei. These changes confound the evaluation of limited postradiation samples. The glycoprotein A-80 is known to be upregulated in prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma. In this study, we assessed the expression of A-80 in radiation-treated prostatic carcinoma. Paraffin sections from 64 postradiation prostatic carcinomas obtained at salvage prostatectomy were immunostained with a monoclonal antibody to A-80; selected sections were doubly immunostained with antibodies to A-80 and various cytokeratin polypeptides. All cases showed readily detectable and often intense staining in the cytoplasm of cancer cells and in intraluminal material of malignant acini. The extent and intensity of the reactions were independent of cancer size and grade. Strong reactions were seen in preserved and distorted acini, clear cell areas, single cancer cells, and in colloid pools with few or no recognizable cancer cells. PIN was present in 34 cases (53{\%}), of which 27 (79{\%}) stained strongly for A-80; atrophic and hyperplastic acini generally did not stain, irrespective of the degree of cellular atypia. The A-80 glycoprotein appears remarkably durable and is readily demonstrable in postradiation prostatic carcinoma despite profound architectural and cytologic changes. This characteristic may prove useful in evaluating small samples for confirmation of diagnosis and determination of extent of residual or recurrent prostatic carcinoma after radiation therapy.",
keywords = "A-80 glycoprotein, Immunohistochemistry, Postradiation, Prostatic carcinoma, Radiation therapy",
author = "Cristina Magi-Galluzzi and Szabo Nagy and Bostwick, {David G.} and Liang Cheng and Gould, {Victor E.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1016/S0046-8177(99)90170-3",
language = "English (US)",
volume = "30",
pages = "1474--1478",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Demonstrability of the glycoprotein A-80 in postradiation prostatic carcinoma

AU - Magi-Galluzzi, Cristina

AU - Nagy, Szabo

AU - Bostwick, David G.

AU - Cheng, Liang

AU - Gould, Victor E.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Radiation therapy results in significant morphological changes in prostatic carcinoma, including decreased cancer size, acinar shrinkage and distortion, cytoplasmic vacuolization, and nuclear pyknosis. Benign acini usually display enlarged, atypical cells with hyperchromatic nuclei. These changes confound the evaluation of limited postradiation samples. The glycoprotein A-80 is known to be upregulated in prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma. In this study, we assessed the expression of A-80 in radiation-treated prostatic carcinoma. Paraffin sections from 64 postradiation prostatic carcinomas obtained at salvage prostatectomy were immunostained with a monoclonal antibody to A-80; selected sections were doubly immunostained with antibodies to A-80 and various cytokeratin polypeptides. All cases showed readily detectable and often intense staining in the cytoplasm of cancer cells and in intraluminal material of malignant acini. The extent and intensity of the reactions were independent of cancer size and grade. Strong reactions were seen in preserved and distorted acini, clear cell areas, single cancer cells, and in colloid pools with few or no recognizable cancer cells. PIN was present in 34 cases (53%), of which 27 (79%) stained strongly for A-80; atrophic and hyperplastic acini generally did not stain, irrespective of the degree of cellular atypia. The A-80 glycoprotein appears remarkably durable and is readily demonstrable in postradiation prostatic carcinoma despite profound architectural and cytologic changes. This characteristic may prove useful in evaluating small samples for confirmation of diagnosis and determination of extent of residual or recurrent prostatic carcinoma after radiation therapy.

AB - Radiation therapy results in significant morphological changes in prostatic carcinoma, including decreased cancer size, acinar shrinkage and distortion, cytoplasmic vacuolization, and nuclear pyknosis. Benign acini usually display enlarged, atypical cells with hyperchromatic nuclei. These changes confound the evaluation of limited postradiation samples. The glycoprotein A-80 is known to be upregulated in prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma. In this study, we assessed the expression of A-80 in radiation-treated prostatic carcinoma. Paraffin sections from 64 postradiation prostatic carcinomas obtained at salvage prostatectomy were immunostained with a monoclonal antibody to A-80; selected sections were doubly immunostained with antibodies to A-80 and various cytokeratin polypeptides. All cases showed readily detectable and often intense staining in the cytoplasm of cancer cells and in intraluminal material of malignant acini. The extent and intensity of the reactions were independent of cancer size and grade. Strong reactions were seen in preserved and distorted acini, clear cell areas, single cancer cells, and in colloid pools with few or no recognizable cancer cells. PIN was present in 34 cases (53%), of which 27 (79%) stained strongly for A-80; atrophic and hyperplastic acini generally did not stain, irrespective of the degree of cellular atypia. The A-80 glycoprotein appears remarkably durable and is readily demonstrable in postradiation prostatic carcinoma despite profound architectural and cytologic changes. This characteristic may prove useful in evaluating small samples for confirmation of diagnosis and determination of extent of residual or recurrent prostatic carcinoma after radiation therapy.

KW - A-80 glycoprotein

KW - Immunohistochemistry

KW - Postradiation

KW - Prostatic carcinoma

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0033403520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033403520&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(99)90170-3

DO - 10.1016/S0046-8177(99)90170-3

M3 - Article

C2 - 10667426

AN - SCOPUS:0033403520

VL - 30

SP - 1474

EP - 1478

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 12

ER -